Nesina and Hyperglycemia - a phase IV clinical study of FDA data

Summary:

Hyperglycemia is reported as a side effect among people who take Nesina (alogliptin benzoate), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Lansoprazole, and have High blood pressure.

The phase IV clinical study analyzes which people have Hyperglycemia when taking Nesina. It is created by eHealthMe based on reports of 2,291 people who have side effects when taking Nesina from the FDA, and is updated regularly.

What is Nesina?

Nesina has active ingredients of alogliptin benzoate. eHealthMe is studying from 2,297 Nesina users. Check the latest studies of Nesina.

What is Hyperglycemia?

Hyperglycemia (high blood sugar) is found to be associated with 1,655 drugs and 2,497 conditions by eHealthMe. Check the latest studies of Hyperglycemia.

On Jul, 15, 2026

2,291 people reported to have side effects when taking Nesina.
Among them, 32 people (1.4%) have Hyperglycemia.

Among these 32 people:

How long have people been on Nesina when they have Hyperglycemia? *

What is the gender of people who have Hyperglycemia when taking Nesina? *

female: 64 %
male: 36 %

What is the age of people who have Hyperglycemia when taking Nesina? *

What are other drugs people take besides Nesina? *

What are other side effects people have besides Hyperglycemia? *

Fever: 5 people, 15.62%
Constipation: 5 people, 15.62%
High Blood Pressure: 4 people, 12.50%
Nausea (feeling of having an urge to vomit): 4 people, 12.50%
White Blood Cell Count Decreased: 3 people, 9.38%
Lymphocyte Count Decreased: 3 people, 9.38%
Anaemia (lack of blood): 3 people, 9.38%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 3 people, 9.38%
Hypoglycemia (low blood sugar): 3 people, 9.38%
Renal Impairment (severely reduced kidney function): 3 people, 9.38%

What are the existing conditions these people have? *

High Blood Pressure: 9 people, 28.12%
Diabetes: 7 people, 21.88%
Type 2 Diabetes: 5 people, 15.62%
Acromegaly (body produces too much growth hormone, leading to excess growth of body tissues): 3 people, 9.38%
Renal Cell Carcinoma (a kidney cancer): 3 people, 9.38%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 3 people, 9.38%
Lupus Nephritis (a chronic inflammatory autoimmune disorder that may affect kidney tissue): 3 people, 9.38%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 2 people, 6.25%
Multiple Myeloma (cancer of the plasma cells): 2 people, 6.25%
Stomatitis (inflammation of mucous membrane of mouth): 2 people, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Nesina and have Hyperglycemia?

- Check whether Hyperglycemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Nesina:

Nesina (2,297 reports)

Hyperglycemia treatments and more:

Hyperglycemia (48,691 reports)

Browse all side effects of Nesina:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperglycemia:

Hyperglycemia (1,655 drugs)

Browse all the conditions that are associated with Hyperglycemia:

Hyperglycemia (2,497 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on alogliptin benzoate (the active ingredients of Nesina) and Nesina (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.